(CercleFinance.com) – DBV Technologies jumped more than 10% this Wednesday on the Paris Stock Exchange after announcing the screening of the first patient in its phase 3 clinical trial in children allergic to peanut.
During a selection visit, the investigating doctor carries out a complete clinical examination of the patient, reads his medical file and checks that the inclusion criteria are met.
If a criterion is not met, the patient is considered not eligible for the study and cannot be included.
The phase 3 study of Viaskin Peanut, a new treatment designed to re-educate the immune system, is to recruit 600 subjects from 80 clinical sites in the United States, Canada, Australia and Europe.
The main measure of effectiveness is the percentage of people responding to treatment in the active arm compared to the placebo arm at month 12.
DBV had been authorized last year to resume the study after having had to modify, at the request of the FDA, certain elements of the protocol so that the study could support a future biological license application (BLA).
DBV plans to screen its last patient in the first half of 2024 before announcing the first results of the trial in the first half of 2025.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
